Epitheliod Sarcoma is a rare childhood and adult cancer with a characteristic loss of the SMARCB1 gene. but are all SMARCB1 loss tumors the same? Context is everything, and perhaps the cell of origin is critical to defining new treatments for this chemotherapy insensitive sarcoma. a role for individualized therapy may also exist. Our review of this entity discussing opportunities for biology-driven new treatments can be viewed here. Co-authors of the review include Dr. Robert Maki from Mt Sinai School of Medicine; Drs. Robin Jones, Khin Thway and Jonathan Noujaim from The Royal Marsden Hospital; and cc-TDI interns Zia and Ayeza.